Cencora, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.

About COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. 

CEO
Robert P. Mauch
CEORobert P. Mauch
Employees
51,000
Employees51,000
Headquarters
Conshohocken, Pennsylvania
HeadquartersConshohocken, Pennsylvania
Founded
1947
Founded1947
Employees
51,000
Employees51,000

COR Key Statistics

Market cap
66.46B
Market cap66.46B
Price-Earnings ratio
19.53
Price-Earnings ratio19.53
Dividend yield
0.68%
Dividend yield0.68%
Average volume
1.44M
Average volume1.44M
High today
$349.80
High today$349.80
Low today
$344.49
Low today$344.49
Open price
$346.97
Open price$346.97
Volume
944.67K
Volume944.67K
52 Week high
$377.54
52 Week high$377.54
52 Week low
$244.82
52 Week low$244.82

Stock Snapshot

The current Cencora, Inc.(COR) stock price is $348.31, with a market capitalization of 66.46B. The stock trades at a price-to-earnings (P/E) ratio of 19.53 and offers a dividend yield of 0.68%.

On 2026-11-18, Cencora, Inc.(COR) stock moved within a range of $344.49 to $349.80. With shares now at $348.31, the stock is trading +1.1% above its intraday low and -0.4% below the session's peak.

Trading volume for Cencora, Inc.(COR) stock has reached 944.67K, versus its average volume of 1.44M.

The stock's 52-week range extends from a low of $244.82 to a high of $377.54.

The stock's 52-week range extends from a low of $244.82 to a high of $377.54.

COR News

TipRanks 18h
Cencora price target raised to $415 from $350 at Barclays

Barclays analyst Glen Santangelo raised the firm’s price target on Cencora (COR) to $415 from $350 and keeps an Overweight rating on the shares. The firm views...

TipRanks 5d
FTC sues to block Covetrus acquiring MWI from Cencora

The Federal Trade Commission sued to block Covetrus and its owners, Clayton, Dubilier & Rice and TPG Inc., from acquiring its closest competitor, MWI Veterinary...

Reuters 5d
US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus - Reuters

...

US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus - Reuters

Analyst ratings

65%

of 17 ratings
Buy
64.7%
Hold
35.3%
Sell
0%

People also own

Based on the portfolios of people who own COR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.